Reading COSM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track COSM free→Reading COSM? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track COSM free→NASDAQHealth CareMedical DistributionSnapshot 2026-06-16
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak. Earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been fairly steady. Risk is high, and the sector backdrop is a headwind. Compared with sector peers, COSM is below typical. There is no valuation input available. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $0.25. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.44x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to Fed net liquidity, the US dollar, long-term interest rates, real (inflation-adjusted) rates.
7 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.24 → $0.01 (+104.2% / 30d). 1 raised, 0 cut, 1 covering analysts.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$296.
How much price usually moves either way.
On a bad day, this stock has moved -$942.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $8,352.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Company momentum fell by 85.6 points (from 55.6 to -30.0).
Composite insight fell by 18.1 points (from 6.4 to -11.7).
Signal changed from 'mixed' to 'cautious'.
As of June 16, 2026, company momentum fell. Composite insight also fell. The signal changed to cautious.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
Manufacturing deal supports revenue growth objective.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
and exhibit 99.1, attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed incorporated by reference in any filing with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended or the Securities Act of 1933, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any filings. Forward Looking Statements Certain…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus peers.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
COSM COSMOS HEALTH INC | Below typical Show detailsSector percentile: 19 of 100 | — | high |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Focus on reaching positive operating cash flow as a near-term milestone.
Newly stated in 2025-Q3. The company has not yet achieved positive operating cash flow, with cash from operating activities at -$1,067,066 in 2026-Q1. The trajectory shows limited progress toward this milestone.
“Positive Operating Cash Flow: A central near-term milestone, marking a turning point.”
Actively expand presence in the U.S. market to drive growth.
Newly stated in 2026-Q1. Revenue was $17.93M in 2026-Q1, down from $19.70M in 2025-Q4. Despite the stated focus on U.S. expansion, revenue has declined, indicating limited progress in driving growth through this initiative.
“Record momentum continues into Q2 2026 with U.S. expansion actively underway.”
Aim to achieve approximately $155.8 million in revenue by the end of 2027.
Newly stated in 2025-Q3. Revenue was $17.93M in 2026-Q1, indicating a significant gap to the $155.8M target by 2027. The current trajectory shows limited progress toward achieving this long-term revenue goal.
Advances: Expand U.S. market presence
Launch of Oliv18 directly expands U.S. market presence.
Advances: Reach $155.8M revenue by 2027
Q1 revenue growth supports revenue target for 2027.
and Exhibit 99.1, attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed incorporated by reference in any filing with the securities and exchange commission under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any filings. Forward Looking Statements Certai…
NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD; TRANSFER OF LISTING On December 11, 2025, Cosmos Health Inc. (the “Company”) received a non-compliance letter from Nasdaq for its failure to maintain a minimum bid price of $1.00 per share for thirty (30) consecutive business days in accordance with Nasdaq Listing Rule 5550(a)(2) (the “Listing Rule”). The Company has one hundred eighty (180) calendar days from December 11, 2025, to regain compliance by maintaining…
RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On November 17, 2025, Cosmos Health Inc., a Nevada corporation (the “Company”), issued a press release announcing its financial results for the quarter and nine months ended September 30, 2025. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference in this
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 30 , 2025, Board of Directors (the “Board”) of the Cosmos Health Inc. (the “Company”) appointed Theodoros C. Karkantzos, effective immediately, to serve as a member of the Board. Mr. Karkantzos was elected a director of the Company at the annual general meeting of the stockholders of the Company on September 30, 2025, with an initial t…
“Key financial objectives by 2027 include: Revenue: Approximately $155.8 million.”